20th Jul 2020 11:54
(Alliance News) - Synairgen PLC on Monday announced positive results from the clinical trial of its antiviral therapy SNG001 in hospitalised Covid-19 patients.
SNG001 is Synairgen's wholly-owned inhaled formulation of interferon beta. It is a proposed treatment for people suffering from chronic obstructive pulmonary disease. The company previously said that two Phase II clinical trials in asthma showed that the inhaled SNG001 treatment activated antiviral pathways in the lung and improved lung function in patients with a respiratory viral infection.
On Monday, the respiratory drug firm said results from the double-blind placebo-controlled trial which tested 101 patients showed that patients who received SNG001 were more than twice as likely to recover from Covid-19 as those on placebo.
Data also showed that patients who received the treatment had a 79% lower risk of developing severe disease compared to the placebo.
It added that the measure of breathlessness was "markedly reduced" in patients who received SNG001.
"We are all delighted with the trial results announced today. This assessment of SNG001 in Covid-19 patients could signal a major breakthrough in the treatment of hospitalised Covid-19 patients. Our efforts are now focused on working with the regulators and other key groups to progress this potential Covid-19 treatment as rapidly as possible," said Chief Executive Richard Marsden.
Shares in Synairgen were trading almost five times higher at 179.00 pence each on Monday morning in London. They closed at 36.40p on Friday.
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Synairgen